Lupin Pharmaceuticals Recalls Over 600,000 Bottles of Hypertension Medication in the U.S., Reports USFDA.
Lupin Pharmaceuticals is recalling over 600,000 bottles of a high blood pressure medication in the United States due to violations of current good manufacturing practices (CGMP), as reported by the U.S. Food and Drug Administration (USFDA).
The recall affects specific lots produced at Lupin’s facility in Goa, India.
The USFDA’s latest Enforcement Report also noted that Dr. Reddy’s Laboratories is recalling a product in the U.S. for similar manufacturing issues. The details regarding the specific products involved in Dr. Reddy’s recall were not disclosed in this report.
This recall comes amid growing scrutiny over pharmaceutical manufacturing practices, particularly concerning the presence of impurities that could pose health risks. In previous incidents, Lupin has faced challenges related to nitrosamine impurities, which are substances that can potentially lead to cancer if consumed over extended periods.
Lupin has stated that it has not received any reports of adverse health effects related to this issue but is proceeding with the recall as a precautionary measure. The affected products were distributed nationwide across various outlets, including wholesalers and pharmacies.
As the situation develops, both companies are working closely with regulatory authorities to ensure consumer safety and compliance with health standards.
Related topics:
